CS
NPCE icon

Credit Suisse’s Neuropace NPCE Stock Holding History

Credit Suisse’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4
Closed – – 4195
2022
Q2 		$0 Buy
+4
New +$26 ﹤0.01% 4180

Other funds holding NPCE

KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Credit Suisse's NPCE Position: Q3 2022 in Review

Credit Suisse sold out of Neuropace (NPCE) in Q3 2022, closing a stake of 4 shares.

Credit Suisse first reported a position in NPCE in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 28 funds tracked by Wall St. Rank hold NPCE as of Q3 2022.

  • Credit Suisse reported no remaining Neuropace position as of Q3 2022 after selling out during the quarter.
  • Credit Suisse sold 4 Neuropace shares in Q3 2022.
  • Credit Suisse first reported a position in Neuropace in Q2 2022 and held it in 1 quarter.
  • Credit Suisse's Neuropace position peaked at $0 in Q2 2022.
  • 28 funds tracked by Wall St. Rank held Neuropace as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.